ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC

Oric Pharmaceuticals, Inc.

$125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.
Pro forma cash into 2H 2027 funds through first ORIC-944 Phase 3 registrational trial primary endpoint.
ORIC-944 + AR inhibitor achieved 59% PSA50 (10/17), 47% confirmed PSA50, and 24% PSA90 (4/17) in heavily pretreated mCRPC.
Safety mostly Grade 1/2 GI events (diarrhea 53%, one Grade 3); no Grade 4/5 treatment-related AEs.
Phase 1b dose optimization in 2H 2025; first global Phase 3 registrational trial expected to start in 1H 2026.

item 1.01item 3.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.